Presbyopia: Corneal Implants- Companies Offering Clinical Trials

Part
01
of one
Part
01

Presbyopia: Corneal Implants- Companies Offering Clinical Trials

Allotex, AcuFocus, Inc., and Carolina Eyecare Physicians are examples of United States-based companies that offer clinical trials regarding corneal implants for presbyopia correction. Equally, in China and France, Xi'an Fourth Hospital and SIFI SpA respectively are inviting applications from qualified individuals. Below is an overview of our findings.

Findings

Our extensive research determined that Allotex, AcuFocus, Inc., Carolina Eyecare Physicians, Xi'an Fourth Hospital, and SIFI SpA are inviting applications from eligible patients meeting their criteria. For each company, we have provided both the start and completion dates. The research team excluded the companies included in the previous Wonder research that did not meet the criteria, and instead, we added new companies that match the requirements. Overall, the links to the websites of the featured companies have been added/highlighted under their names.

Allotex

United States-based Allotex, Inc. has sponsored a clinical trial to determine the effectiveness and safety of intrastromal implantation of its "TransForm™ Corneal Allograft (TCA)" for achieving near vision in patients with presbyopia. Eligible applicants must be aged from 41 to 65 years. Moreover, in the U.S., the applications must be addressed to Allotex, Inc. via phone (617-391-9544) or address (Allotex, Inc., 27-43 Wormwood Street, Suite 160, Boston MA 02210). The actual start date for the study was September 9, 2018; however, the completion date is yet to be determined. Presently, recruitment is ongoing according to calls for registration posted on Allotex's website and published in press releases.

ACUFOCUS, INC. 

United States-based AcuFocus, Inc. has sponsored a clinical trial to determine whether it can achieve near or immediate vision with the implantation of "IC-8 intraocular lens (IOL)" in one eye and "monofocal toric IOL" in the other eye or with the implantation of "monofocal toric IOL" in both eyes. Applicants wishing to participate in the trials must be aged 22 years and above. Applications are made via phone (949-585-9511 ext 106) to Magda Michna, PhD., or email at (mmichna@acufocus.com). The study commenced on December 4, 2018, and shall run until May 30, 2020.

CAROLINA EYECARE PHYSICIANS, LLC 

United States-based Carolina Eyecare Physicians has sponsored a clinical trial to determine the results of the combination of a multifocal IOL and an EDOF IOL in the treatment of presbyopia by "undergoing routine cataract surgery." The trial is open to patients aged 40 years and above and "undergoing bilateral cataract extraction with intraocular lens implantation." Applicants should contact Helga P Sandoval via phone at (843-881-3937) or email at (helga.sandoval@carolinaeyecare.com). The study started on December 7, 2018, and will end on March 31, 2020.

XI'AN FOURTH HOSPITAL

China-based Xi'an Fourth Hospital has sponsored a clinical trial for the implantation of "trifocal intraocular lens" for the correction of presbyopia for patients who have undergone cataract surgery. The trial is open to cataract patients with corneal astigmatism of less than 1.5D and clear cognitive function, among other criteria. Applicants should contact Meifang Chu via phone at (+86 18602948320) or email at (2567437874@qq.com). The study commenced on July 01, 2017, and will end on December 31, 2019.

SIFI SpA

Italian company SIFI SpA has sponsored a clinical trial to investigate the visual performance of the "extended depth of focus by Intraocular Lens MINI WELL READY®" against the outcomes of the "trifocal Intraocular Lens FineVision®" in the treatment of cataract and presbyopia. The trials will be held in France and will run between February 10, 2019, and April 2020. Applicants should contact Gianluca Stivale via phone at (+39-095-792-2335) or email at (gianluca.stivale@sifigroup.com) or Dionisio Barattini via phone at (+39-335-543-7574) or email at (barattini@operacro.com).
Sources
Sources